← stocks-llm Find companies like ZSQR →

Z SQUARED INC (ZSQR)

Health Care · Biopharmaceutical cell therapy and immunotherapy development · NASDAQ

An early-stage biopharmaceutical company developing natural killer cell therapies and CAR platforms for cancer and infectious diseases, complemented by enterprise software capabilities.

What Z SQUARED INC does

Z Squared Inc (formerly Coeptis Therapeutics Holdings) is a biopharmaceutical and technology company developing cell therapy platforms and immunotherapies for cancer, autoimmune, and infectious diseases. The company operates through subsidiaries including SNAP Biosciences and GEAR Therapeutics, focusing on NK cell therapies and CAR-T platforms, while also offering AI-powered marketing software and robotic process automation tools.

Themes: ["Cell therapy / NK cell immunotherapy","CAR-T and CAR-NK platforms","Cancer therapeutics","Infectious disease treatment","Autoimmune disease","Enterprise AI / process automation"]

Fundamentals

Ask why ZSQR looks like this →

Key risks (from latest filing)

["Highly unprofitable with accumulated deficit of $113.9M and negative net margin of -832%, with no clear path to profitability; company is burning cash rapidly with limited runway.","All product candidates remain in pre-clinical or early Phase I/II stages with significant development risk; no approved therapies or near-term revenue generation expected.","Convertible notes in default ($100K) and dependent on equity financing and strategic partnerships (SSA with Deverra ended December 2024); significant dilution risk to shareholders from continued fundraising."]

See ZSQR's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.